GlassScriptPhysician profile
Celeste S Chang
NPI 1245633825
$5,033.71
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $916 · 2020: $241 · 2021: $1,088 · 2022: $1,554 · 2023: $1,215 · 2024: $19.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,126 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,125.94 |
| Education | $108.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $844.06 | 2019-2023 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $656.43 | 2019-2023 | Jynarque |
| Esperion Therapeutics, INC. | $557.30 | 2021-2023 | Nexletol |
| Fresenius USA Marketing, INC. | $432.37 | 2019-2023 | Velphoro |
| Glaxosmithkline, LLC. | $424.73 | 2020-2023 | Benlysta |
| Vifor Pharma, INC. | $376.44 | 2019-2023 | Korsuva, Veltassa |
| Boston Scientific Corporation | $257.47 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $230.96 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $226.15 | 2022-2023 | |
| Opko Pharmaceuticals, LLC | $213.64 | 2019-2023 | Rayaldee |
| Amarin Pharma, INC. | $172.87 | 2020-2022 | |
| Horizon Therapeutics Plc | $154.76 | 2020-2023 | Krystexxa |
| Travere Therapeutics, INC. | $86.97 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $83.58 | 2023-2024 | Gemtesa |
| Mallinckrodt Enterprises LLC | $83.37 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $75.90 | 2019-2023 | Gattex |
| Sunovion Pharmaceuticals INC. | $26.42 | 2022 | |
| Akebia Therapeutics INC | $22.29 | 2023 | Auryxia |
| Ibsa Pharma INC. | $20.95 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.04 | 2019 | |
| Arbor Pharmaceuticals, INC. | $19.69 | 2021 | |
| Calliditas Therapeutics US INC. | $18.16 | 2023 | Tarpeyo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 | |
| Abbvie INC. | $12.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celeste Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.